STOCKNO.DE
Institutional ownership intelligence
Research
Schedule 13G/A

LEGN Schedule 13G/A filing by T. Rowe Price Associates

T. Rowe Price Associates reported beneficial ownership of 11.1M shares, representing 6.1% of Legend Biotech Corp in this filing.

FiledNov 14, 2024
Ownership dateSep 30, 2024
Reported shares11.1M
Reported ownership6.1%
Ownership details

Voting and dispositive power reported in the filing

These figures describe the reporting filer’s disclosed voting and investment authority. They should be read together with the reported share count and percentage.

Sole voting power 10.8M
Shared voting power 0
Sole dispositive power 11.2M
Shared dispositive power 0
Price context

Price dates alongside the ownership filing

Price data provides market context around the disclosure. It does not identify the filer’s actual transaction price.

Close near filing date$39.89as of Nov 14, 2024
Latest tracked price$19.05as of Aug 5, 2026
Source

Original filing and accession

Use the SEC filing as the primary source when you need the complete disclosure, footnotes, exhibits, or reporting-person details.

Reporting filer
T. Rowe Price Associates
CIK
CIK0000080255
Accession
0000080255-24-001457
Form
Schedule 13G/A
Open SEC filing View LEGN ownership history
Read the filing in context

Understand what a Schedule 13 filing does—and does not—tell you.

How to read a Schedule 13G → Does a 13G mean the shares were just bought? → Filing date vs. ownership date →